Current landscape and future directions for systemic treatments of hepatocellular carcinoma

References

[1] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[2] da Fonseca LG,Braghiroli MIFM.Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.BMC Cancer2018;18:1250 PMCID:PMC6293528

[3] Nault JC,Caruso S.Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma.Hepatology2020;71:164-82

[4] Cheng AL,Chen Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009;10:25-34

[5] Llovet JM,Mazzaferro V.SHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinoma.N Engl J Med2008;359:378-90

[6] Bruix J,Merle P.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[7] Finn RS,Granito A.Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial.J Hepatol2018;69:353-8

[8] Kudo M,Qin S.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-73

[9] Abou-Alfa GK,Cheng A-L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.N Engl J Med2018;379:54-63 PMCID:PMC7523244

[10] Zhu AX,Yen CJ.REACH-2 study investigatorsRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019;20:282-96

[11] Ramadori G,Grabbe E,Armbrust T.Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis.Anticancer Drugs2004;15:405-9

[12] Cheng AL,Ikeda M.Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022;76:862-73 PMCID:PMC9630017

[13] Abou-alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evidence2022;1

[14] Singal AG,Yarchoan M.AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.Hepatology2023;Online ahead of print:

[15] D'Alessio A,Nishida N.Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study..Hepatology2022;76:1000-12

[16] El Hajra I,Sapena V.Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis.Hepatology2023;77:1139-49

[17] Marrero JA,Venook AP.Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study.J Hepatol2016;65:1140-7

[18] Daniele G,Arenare L.BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function.Hepatoma Res2021;7:61

[19] Anugwom CM,Debes JD.Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.Hepatoma Res2022;8:7 PMCID:PMC9181209

[20] Hack SP,Chen M.IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Future Oncol2020;16:975-89

[21] Kudo M,Chan S.Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study.Cancers2019;11:1084 PMCID:PMC6721438